ribociclib
novartis
['natalee', ' ribo', 'ribociclib']
results from the natalee trial delivered with 27.7 months f/u for pfs : the addition of 3 years of ribociclib (at 400mg dose) is associated to 26 % risk reduction in idfs (all subgrouos) and ddfs . about 40% of intermediate risk patients included. f/u continues.
#asco2023 
Mare de 2 fills. Oncòloga a H.Vall D'Hebron i VHIO. Curiosa. Caòtica dins d'un ordre. Al.lèrgica als  convencionalismes sense ànima. #BreastCancer,   @SOLTI